Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting

BACKGROUND: Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Using a novel electronic reporting tool, we aimed to prospectively describe the onset of tofacitinib efficacy during induction therapy in a real-world study. METHODS: Patient-reported outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Millie D, Afzali, Anita, Fischer, Monika, Hudesman, David, Abdalla, Maisa, McCabe, Robert, Cohen, Benjamin L, Ungaro, Ryan C, Harlan, Will, Hanson, John, Konijeti, Gauree, Polyak, Steven, Ritter, Timothy, Salzberg, Bruce, Seminerio, Jennifer, English, Emily, Zhang, Xian, Sharma, Puza P, Herfarth, Hans H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069660/
https://www.ncbi.nlm.nih.gov/pubmed/35700276
http://dx.doi.org/10.1093/ibd/izac121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069660/
https://www.ncbi.nlm.nih.gov/pubmed/35700276
http://dx.doi.org/10.1093/ibd/izac121

Ejemplares similares